Switch theme
Sign up to access all valuation multiples
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
2010
6
LTM Revenue $0.9M
LTM EBITDA -$3.0M
$0.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lipigon Pharmaceuticals has a last 12-month revenue (LTM) of $0.9M and a last 12-month EBITDA of -$3.0M.
In the most recent fiscal year, Lipigon Pharmaceuticals achieved revenue of $1.1M and an EBITDA of -$2.6M.
Lipigon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lipigon Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $0.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.0M | XXX | -$2.6M | XXX | XXX | XXX |
| EBITDA Margin | -332% | XXX | -244% | XXX | XXX | XXX |
| EBIT | -$3.0M | XXX | -$2.6M | XXX | XXX | XXX |
| EBIT Margin | -333% | XXX | -249% | XXX | XXX | XXX |
| Net Profit | -$2.9M | XXX | -$2.6M | XXX | XXX | XXX |
| Net Margin | -331% | XXX | -246% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lipigon Pharmaceuticals's stock price is SEK 0 (or $0).
Lipigon Pharmaceuticals has current market cap of SEK 16.9M (or $1.7M), and EV of SEK 5.2M (or $0.5M).
See Lipigon Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.5M | $1.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lipigon Pharmaceuticals has market cap of $1.7M and EV of $0.5M.
Lipigon Pharmaceuticals's trades at 0.5x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Lipigon Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lipigon Pharmaceuticals has a P/E ratio of -0.6x.
See valuation multiples for Lipigon Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7M | XXX | $1.7M | XXX | XXX | XXX |
| EV (current) | $0.5M | XXX | $0.5M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLipigon Pharmaceuticals's last 12 month revenue growth is 105%
Lipigon Pharmaceuticals's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.
Lipigon Pharmaceuticals's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lipigon Pharmaceuticals's rule of X is -71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lipigon Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 105% | XXX | 86% | XXX | XXX | XXX |
| EBITDA Margin | -332% | XXX | -244% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | -140% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 349% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lipigon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Lipigon Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Lipigon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lipigon Pharmaceuticals founded? | Lipigon Pharmaceuticals was founded in 2010. |
| Where is Lipigon Pharmaceuticals headquartered? | Lipigon Pharmaceuticals is headquartered in Sweden. |
| How many employees does Lipigon Pharmaceuticals have? | As of today, Lipigon Pharmaceuticals has 6 employees. |
| Is Lipigon Pharmaceuticals publicy listed? | Yes, Lipigon Pharmaceuticals is a public company listed on STO. |
| What is the stock symbol of Lipigon Pharmaceuticals? | Lipigon Pharmaceuticals trades under LPGO ticker. |
| When did Lipigon Pharmaceuticals go public? | Lipigon Pharmaceuticals went public in 2021. |
| Who are competitors of Lipigon Pharmaceuticals? | Similar companies to Lipigon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lipigon Pharmaceuticals? | Lipigon Pharmaceuticals's current market cap is $1.7M |
| What is the current revenue of Lipigon Pharmaceuticals? | Lipigon Pharmaceuticals's last 12 months revenue is $0.9M. |
| What is the current revenue growth of Lipigon Pharmaceuticals? | Lipigon Pharmaceuticals revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of Lipigon Pharmaceuticals? | Current revenue multiple of Lipigon Pharmaceuticals is 0.6x. |
| Is Lipigon Pharmaceuticals profitable? | Yes, Lipigon Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lipigon Pharmaceuticals? | Lipigon Pharmaceuticals's last 12 months EBITDA is -$3.0M. |
| What is Lipigon Pharmaceuticals's EBITDA margin? | Lipigon Pharmaceuticals's last 12 months EBITDA margin is -332%. |
| What is the current EV/EBITDA multiple of Lipigon Pharmaceuticals? | Current EBITDA multiple of Lipigon Pharmaceuticals is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
